GlaxoSmithKline has predicted a return to growth in China next year as it slowly begins to repair the damage from a corruption scandal which shattered the company’s reputation in one of the world’s most important pharmaceuticals markets.
葛蘭素史克(GSK)預計，明年其在華業務將恢復增長。該公司正慢慢著手修復一樁腐敗丑聞造成的損害，那樁丑聞令該公司在全球最重要的制藥市場之一聲譽掃地。
您已閱讀14%（311字），剩余86%（1856字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。